Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call


FREMONT, Calif., Aug. 1, 2018 /PRNewswire/ -- Ardelyx Inc. (NASDAQ: ARDX) today announced that it plans to report its second quarter 2018 financial results after market close on Tuesday, August 7, 2018. Management will host a conference call and webcast that afternoon at 4:30 p.m. ET to discuss the results and other business updates.

To participate in the conference call, please dial (855) 296-9612 (toll-free) or (920) 663-6277 (toll) and reference call ID number 1592643. A webcast of the call can be accessed by visiting the Investor section of the Ardelyx website at A replay of the webcast will be available on the Ardelyx website for 60 days following the call.

About Ardelyx, Inc.
Ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. Ardelyx's renal pipeline includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx has completed Phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a New Drug Application to the U.S. Food and Drug Administration for this indication in the second half of 2018. To efficiently bring its treatments to market, Ardelyx is pursuing strategic collaborations in the U.S. and outside the U.S., with established agreements with Kyowa Hakko Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada. For more information, please visit and connect with us on Twitter @Ardelyx.


View original content with multimedia:

SOURCE Ardelyx

Company Codes: NASDAQ-NMS:ARDX

Back to news